Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H13NO2S |
| Molecular Weight | 223.291 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
S=C1NCCC(COC2=CC=CC=C2)O1
InChI
InChIKey=NIPRGEWHJUTVQK-UHFFFAOYSA-N
InChI=1S/C11H13NO2S/c15-11-12-7-6-10(14-11)8-13-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,12,15)
| Molecular Formula | C11H13NO2S |
| Molecular Weight | 223.291 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/277105
Sources: https://www.ncbi.nlm.nih.gov/pubmed/277105
Tifemoxone is a tetrahydrooxazine derivative patented by Delalande S.A. as an analgesic, spasmolytic, antidepressive agent. In preclinical studies, Tifemoxone caused thyreotoxicity, hairlessness and increased in water consumption and diuresis and in addition it had a strong hepatotoxic effect especially in the dog.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/277105
rat: 0, 85 and 230 mg/kg/d
dog: 0, 55 and 300 mg/kg/d.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:07:55 GMT 2025
by
admin
on
Mon Mar 31 18:07:55 GMT 2025
|
| Record UNII |
09I93HJ3Y4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB11037MIG
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
3033964
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
3747
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
09I93HJ3Y4
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
39754-64-8
Created by
admin on Mon Mar 31 18:07:55 GMT 2025 , Edited by admin on Mon Mar 31 18:07:55 GMT 2025
|
PRIMARY | |||
|
DTXSID50865969
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
C75184
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105445
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
C017760
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
254-620-3
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY | |||
|
100000082191
Created by
admin on Mon Mar 31 18:07:56 GMT 2025 , Edited by admin on Mon Mar 31 18:07:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |